Résumé :
|
[BDSP. Notice produite par INIST-CNRS tR0xDIGF. Diffusion soumise à autorisation]. Uncertainty continues as to whether treatments for ovulation induction are associated with increased risk of cancer. The authors conducted a long-term population-based historical cohort study of parous women. A total of 15,030 women in the Jerusalem Perinatal Study who gave birth in 1974-1976 participated in a postpartum survey. Cancer incidence through 2004 was analyzed using Cox's proportional hazards models, controlling for age and other covariates. Women who used drugs to induce ovulation (n=567) had increased risks of cancer at any site (multivariate hazard ratio (HR)=1.36,95% confidence interval (Cl) : 1.06,1.74). An increased risk of uterine cancer was found among women treated with ovulation-inducing agents (HR=3.39,95% Cl : 1.28,8.97), specifically clomiphene (HR=4.56,95% Cl : 1.56,13.34). No association was noted between use of ovulation-inducing agents and ovarian cancer (age-adjusted HR=0.61,95% Cl : 0.08,4.42). Ovulation induction was associated with a borderline-significant increased risk of breast cancer (multivariate HR=1.42,95% Cl : 0.99,2.05). Increased risks were also observed for malignant melanoma and non-Hodgkin lymphoma. These associations appeared stronger among women who waited more than 1 year to conceive. Additional follow-up studies assessing these associations by drug type, dosage, and duration are needed.
|